Durvalumab plus other medicines for peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests how well durvalumab (an immune therapy) works with other medicines—either with or without pralatrexate, romidepsin, and oral 5-azacitidine—to treat peripheral T-cell lymphoma. It may help people with newly diagnosed or relapsed/refractory disease by strengthening the immune attack on the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old and can sign informed consent.
- You have peripheral T-cell lymphoma confirmed by biopsy (either newly diagnosed or relapsed/refractory).
- If your lymphoma has relapsed/refractory, you’ve had at least one prior treatment.
- Your lymphoma can be measured or assessed by the study team (evaluable/measurable disease).
- Your general health is good enough (ECOG 2 or less) and your organs/bone marrow work adequately on blood/urine tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests whether an oral drug (azacytidine) plus romidepsin works better than a standard “doctor’s choice” treatment for people with relapsed or refractory peripheral T-cell lymphoma. It’s for adults whose disease has come back or did not respond after prior treatment.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Hear when a new Lymphoma, T-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.